A review of abuse-deterrent opioids for chronic nonmalignant pain.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

26 citing papers in PubMed, 72 citations in OpenAlex.

1. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.Advances in therapy · 2019
   Trial
2. Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study.Advances in therapy · 2019
   Trial
3. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation.Pain medicine (Malden, Mass.) · 2019
   Trial
4. Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users.Pain medicine (Malden, Mass.) · 2018
   Trial
5. Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects.Pain research & management · 2018
   Trial
6. A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone.Pain medicine (Malden, Mass.) · 2016
   Trial
7. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.Clinical drug investigation · 2015
   Trial
8. Differential Effects of Cannabidiol and a Novel Cannabidiol Analog on Oxycodone Place Preference and Analgesia in Mice: an Opioid Abuse Deterrent with Analgesic Properties.Cannabis and cannabinoid research · 2022
   Article
9. Self-regulated Anti-Overdose Crush and Extraction-Resistant Drug Delivery System to Combat Opioid Overdose Crisis.AAPS PharmSciTech · 2022
   Article
10. Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS).Pharmaceuticals (Basel, Switzerland) · 2022
    Article
11. A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin.ClinicoEconomics and outcomes research : CEOR · 2022
    Article
12. Acute Pain Management of Chronic Pain Patients in Ambulatory Surgery Centers.Current pain and headache reports · 2021
    Review
13. Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients.British journal of clinical pharmacology · 2020
    Article
14. Using natural language processing of clinical text to enhance identification of opioid-related overdoses in electronic health records data.Pharmacoepidemiology and drug safety · 2019
    Article
15. Pharmacovigilance in perspective: drug withdrawals, data mining and policy implications.F1000Research · 2019
    Review
16. Relative Bioavailability, Intranasal Abuse Potential, and Safety of Benzhydrocodone/Acetaminophen Compared with Hydrocodone Bitartrate/Acetaminophen in Recreational Drug Abusers.Pain medicine (Malden, Mass.) · 2018
    Article
17. Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone.Journal of pain research · 2018
    Article
18. In Vitro Drug Release After Crushing: Evaluation of XtampzaClinical drug investigation · 2017
    Article
19. Design of modular dual enzyme-responsive peptides.Biopolymers · 2017
    Article
20. Management of Patients on Abuse-Deterrent Opioids in the Ambulatory Surgery Setting.Current pain and headache reports · 2017
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract